ThomasJ, KarverS, CooneyGA, ChamberlainBH, WattCK, SlatkinNE, StamblerN, KremerAB, IsraelRJ. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med, 2008; 358,22:2332–2343.
3.
FossJF, BassAS, GoldbergLI. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol, 1993; 33:747–751.
4.
YuanCS, WeiG, FossJF. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects. JPET, 2002; 300:118–123.
5.
JohnstonKD. The potential for μ-opioid receptor agonists to be anti-emetic in humans: Review of clinical data. Acta Anaesthesiol Scand, 2010; 54:132–140.
6.
RuddJA, ChengCH, NaylorRJ, NganMP, WaiMK. Modulation of emesis by fentanyl and opioid receptor antagonists in Suncus murinus. Eur J Pharmacol, 1999; 374:77.
7.
MoskowitzAS, GoodmanRR. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Res, 1985; 360:117–129.
